Most Popular - It’s been a great week for Medicinova (MNOV) shareholders, who saw their holdings climb as much as 80% with the announcement that the company’s lead … Continue Reading
Read NowMost Popular - The Home Health Services industry remains under pressure due to regulatory scrutiny and looming reimbursement cuts. As we have written in the past, Amedisys, Inc. … Continue Reading
Read NowLong Ideas - On Friday, PropThink launched its database of Special Protocol Assessments, or SPAs. These trials are, in essence, a FDA-blessed measure to mitigate clinical efficacy risk … Continue Reading
Read NowResearch - The hope remains alive that Optimer (OPTR) will somehow power through a disappointing launch and increase prescription growth sufficiently to offset the 25% discount that … Continue Reading
Read NowMost Popular - Shares of ResMed Inc. (RMD) have finally found their top, peaking at $48.37 in late January before dropping to the $43 level. But the downslide … Continue Reading
Read NowMost Popular - Shares of Ampio Pharmaceuticals (AMPE) were on a tear in the past four weeks, climbing from $3.39 at the end of December to a recent … Continue Reading
Read NowLong Ideas - The highlight of our week was Allergan’s ~$1B buyout of MAP Pharmaceuticals, a company that we recommended in early January. The acquisition came at a … Continue Reading
Read Now